14.99
-0.06 (-0.40%)
| Penutupan Terdahulu | 15.05 |
| Buka | 14.44 |
| Jumlah Dagangan | 5,400 |
| Purata Dagangan (3B) | 45,391 |
| Modal Pasaran | 382,939,040 |
| Harga / Jualan (P/S) | 2.77 |
| Harga / Buku (P/B) | 4.63 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2025 - 16 May 2025 |
| EPS Cair (TTM) | -0.620 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.18% |
| Nisbah Semasa (MRQ) | 25.48 |
| Aliran Tunai Operasi (OCF TTM) | -21.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -15.39 M |
| Pulangan Atas Aset (ROA TTM) | -29.99% |
| Pulangan Atas Ekuiti (ROE TTM) | -46.85% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Benitec Biopharma Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.25 |
|
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.20% |
| % Dimiliki oleh Institusi | 82.21% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Lion Point Capital, Lp | 31 Dec 2024 | 62,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 28.00 (HC Wainwright & Co., 86.79%) | Beli |
| Median | 20.00 (33.42%) | |
| Rendah | 18.00 (Citizens Capital Markets, 20.08%) | Beli |
| Purata | 22.00 (46.77%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 14.33 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 May 2025 | 28.00 (86.79%) | Beli | 13.98 |
| 24 Mar 2025 | 28.00 (86.79%) | Beli | 14.34 | |
| JMP Securities | 15 May 2025 | 20.00 (33.42%) | Beli | 13.50 |
| 10 Apr 2025 | 20.00 (33.42%) | Beli | 11.94 | |
| Citizens Capital Markets | 18 Mar 2025 | 18.00 (20.08%) | Beli | 15.52 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 May 2025 | Pengumuman | Benitec Biopharma Releases Third Quarter 2025 Financial Results |
| 25 Mar 2025 | Pengumuman | Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering |
| 19 Mar 2025 | Pengumuman | Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference |
| 26 Feb 2025 | Pengumuman | Benitec Biopharma to Participate in Upcoming Conferences in March |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 01 Jun 2018 | - | 08 Jun 2018 | 0.002929 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2018 | 0.003 | 1 | 0.00 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |